$PLPL Plandai Has Huge Opportunity With Its Malari

[b]$PLPL[/b] Plandai Has Huge Opportunity With Its Malaria Treatment

BALTIMORE, MD, [b][color=green]May 31, 2013[/color][/b] (Marketwired via COMTEX) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, posits that given its high degree of bioavailability Plandai Biotechnology, Inc. (OTCQB: PLPL) could change the way the market and consumer utilize green tea extracts. Plandai Biotechnology, Inc. (OTCQB: PLPL) is a developer of highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.

Green tea, or green tea extracts are some of the most popular products in the wellness nutraceutical segment. Its gallate catechins are known to have been used extremely effectively and efficiently as an antioxidant, weight loss aid by increasing metabolism, cold prevention, oral health, and cardiovascular health. Yet, due to the nature of how the gallate catechins are typically extracted from dry leaves, the overwhelming majority of these products have low bioavailability of perhaps 10%, meaning that the rate to which an active ingredient can be absorbed by the body's tissues is not very high.

Conversely, according to published USDA studies, the Plandai-grown product has demonstrated to have improved bioavailability over other products by 60-80%, far exceeding anything currently available today. In order to obtain the same bioavailability from competing products currently in the market, consumers would have to purchase and consume anywhere from 6-8 times as much product to generate an equivalent efficacy.

Based on the announcement of development and distribution agreements, Plandai's (green tea) Catechin Extract should become widely available via nutraceutical products, in late 2013. Given their substantially higher bioavailability, once these products become available, it should have a tremendous impact on Plandai (OTCQB: PLPL) and the entire nutrition market.

Additional detail via the Goldman Small Cap Research article as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented Phytofare(TM) extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.